Sunitinib Inhibits MEK/ERK and SAPK/JNK Pathways and Increases Sodium/Iodide Symporter Expression in...
Sunitinib Inhibits MEK/ERK and SAPK/JNK Pathways and Increases Sodium/Iodide Symporter Expression in Papillary Thyroid Cancer
About this item
Full title
Author / Creator
Publisher
United States: Mary Ann Liebert, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Mary Ann Liebert, Inc
Subjects
More information
Scope and Contents
Contents
Background:
Sunitinib malate (Sutent
®
, Pfizer, Inc.; SU11248) is a selective, multitargeted inhibitor of receptor tyrosine kinases and has been shown to inhibit receptors for VEGF, PDGF, KIT, FLT3, and RET. The objective of this study was to determine the effects of sunitinib on signal transduction pathways and on gene expression of iodi...
Alternative Titles
Full title
Sunitinib Inhibits MEK/ERK and SAPK/JNK Pathways and Increases Sodium/Iodide Symporter Expression in Papillary Thyroid Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_754028118
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_754028118
Other Identifiers
ISSN
1050-7256
E-ISSN
1557-9077
DOI
10.1089/thy.2010.0008
